AIM
HTGM

Alambic Investment Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Alambic Investment Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-128
Closed -$38K – 372
2019
Q2 		$38K Buy
+128
New +$53.4K 0.02% 290

Other funds holding HTGM

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Alambic Investment Management's HTGM Position: Q3 2019 in Review

Alambic Investment Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2019, closing a stake of 128 shares — an estimated $38K sold.

Alambic Investment Management first reported a position in HTGM in Q2 2019 and held it in 1 quarter. The position peaked at $38K in Q2 2019. 44 funds tracked by Wall St. Rank hold HTGM as of Q3 2019.

  • Alambic Investment Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Alambic Investment Management sold 128 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2019, an estimated $38K.
  • Alambic Investment Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Alambic Investment Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $38K in Q2 2019.
  • 44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2019.

Based on Alambic Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.